These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30868895)

  • 1. The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells.
    Xiao H; Claret FX; Shen Q
    Neoplasma; 2019 May; 66(3):481-486. PubMed ID: 30868895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
    Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inhibition of the COP9 signalosome for treatment of cancer.
    Schlierf A; Altmann E; Quancard J; Jefferson AB; Assenberg R; Renatus M; Jones M; Hassiepen U; Schaefer M; Kiffe M; Weiss A; Wiesmann C; Sedrani R; Eder J; Martoglio B
    Nat Commun; 2016 Oct; 7():13166. PubMed ID: 27774986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Let-7d Inhibits Growth and Metastasis in Breast Cancer by Targeting Jab1/Cops5.
    Wei Y; Liu G; Wu B; Yuan Y; Pan Y
    Cell Physiol Biochem; 2018; 47(5):2126-2135. PubMed ID: 29975923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSN5/Jab1 facilitates non-small cell lung cancer cell growth through stabilizing survivin.
    Li J; Li Y; Wang B; Ma Y; Chen P
    Biochem Biophys Res Commun; 2018 Jun; 500(2):132-138. PubMed ID: 29596838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
    Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
    Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo.
    Samsa WE; Mamidi MK; Bashur LA; Elliott R; Miron A; Chen Y; Lee B; Greenfield EM; Chan R; Danielpour D; Zhou G
    Oncogene; 2020 Jun; 39(23):4581-4591. PubMed ID: 32390003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells.
    Jumpertz S; Hennes T; Asare Y; Schütz AK; Bernhagen J
    Cell Signal; 2017 Jun; 34():38-46. PubMed ID: 28229932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer.
    Guo Z; Wang Y; Zhao Y; Shu Y; Liu Z; Zhou H; Wang H; Zhang W
    Gene; 2019 Mar; 687():219-227. PubMed ID: 30468907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
    Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
    Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway.
    Zhu Y; Qiu Z; Zhang X; Qian F; Wang B; Wang L; Shi H; Yu R
    J Neurooncol; 2017 Jan; 131(1):31-39. PubMed ID: 27640199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome.
    Pandey P; Siddiqui MH; Behari A; Kapoor VK; Mishra K; Sayyed U; Tiwari RK; Shekh R; Bajpai P
    Anticancer Agents Med Chem; 2019; 19(16):2019-2033. PubMed ID: 31345154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
    Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
    J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Approach to Unraveling the Apoptotic Potential of Rutin (Bioflavonoid) via Targeting
    Pandey P; Khan F; Alzahrani FA; Qari HA; Oves M
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma.
    Pan Y; Wang M; Bu X; Zuo Y; Wang S; Wang D; Liu Q; Su B; Xu T; Wang C; Claret FX; Yang H
    BMC Cancer; 2013 Jul; 13():323. PubMed ID: 23815987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor 1 promoter-induced JAB1 overexpression enhances chemotherapeutic sensitivity of lung cancer cell line A549 in an anoxic environment.
    Hu MD; Xu JC; Fan Y; Xie QC; Li Q; Zhou CX; Mao M; Yang Y
    Asian Pac J Cancer Prev; 2012; 13(5):2115-20. PubMed ID: 22901179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging roles of Jab1/CSN5 in cancer.
    Wang L; Zheng JN; Pei DS
    Med Oncol; 2016 Aug; 33(8):90. PubMed ID: 27412572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple functions of Jab1 are required for early embryonic development and growth potential in mice.
    Tomoda K; Yoneda-Kato N; Fukumoto A; Yamanaka S; Kato JY
    J Biol Chem; 2004 Oct; 279(41):43013-8. PubMed ID: 15299027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.
    Mazzu YZ; Liao YR; Nandakumar S; Jehane LE; Koche RP; Rajanala SH; Li R; Zhao H; Gerke TA; Chakraborty G; Lee GM; Nanjangud GJ; Gopalan A; Chen Y; Kantoff PW
    Oncogene; 2022 Jan; 41(5):671-682. PubMed ID: 34802033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma.
    Pandey P; Bajpai P; Siddiqui MH; Sayyed U; Tiwari R; Shekh R; Mishra K; Kapoor VK
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):826-837. PubMed ID: 30727937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.